Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 May 1994Website:
http://www.nektar.comNext earnings report:
04 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:25:15 GMTDividend
Analysts recommendations
Institutional Ownership
NKTR Latest News
Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, although these are only small studies. NKTR-255 also has a potential near-term readout in the JAVELIN Bladder Medley study, although there is competition.
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.
SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023.
SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m.
SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials - SAN FRANCISCO , Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO). Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that enhances the activity of regulatory T cells (Tregs) with promising dose-dependent clinical activity across multiple physician-assessed and patient-reported endpoints for AD and PsO.
– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved complete remission, all without detectable MRD – SAN FRANCISCO , Oct. 17, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in Blood, the peer-reviewed medical journal of the American Society of Hematology. NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors.
- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN FRANCISCO , Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress.
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 1(current)
- 2
What type of business is Nektar Therapeutics?
Nektar Therapeutics is a research biopharmaceutical company. Founded in 1990 in California. Currently registered in Delaware in 1998. The company's activities are focused on the development of innovative drugs. Research and development include potential methods for treating cancer and autoimmune diseases. In the field of immuno-oncology, drugs are being developed to stimulate and support the body's immune response to fight cancer. The biological drug bempegaldesleukin (NKTR-214) is the main development in this area. In the treatment of autoimmune diseases, the company is developing the drug NKTR-358. The drug has undergone trials for the treatment of systemic lupus erythematosus, psoriasis, and atopic dermatitis. MOVANTIK is a drug for the treatment of constipation caused by opioids, a side effect of chronic use of prescription opioid analgesics.
What sector is Nektar Therapeutics in?
Nektar Therapeutics is in the Healthcare sector
What industry is Nektar Therapeutics in?
Nektar Therapeutics is in the Biotechnology industry
What country is Nektar Therapeutics from?
Nektar Therapeutics is headquartered in United States
When did Nektar Therapeutics go public?
Nektar Therapeutics initial public offering (IPO) was on 03 May 1994
What is Nektar Therapeutics website?
https://www.nektar.com
Is Nektar Therapeutics in the S&P 500?
No, Nektar Therapeutics is not included in the S&P 500 index
Is Nektar Therapeutics in the NASDAQ 100?
No, Nektar Therapeutics is not included in the NASDAQ 100 index
Is Nektar Therapeutics in the Dow Jones?
No, Nektar Therapeutics is not included in the Dow Jones index
When was Nektar Therapeutics the previous earnings report?
No data
When does Nektar Therapeutics earnings report?
The next expected earnings date for Nektar Therapeutics is 04 March 2025